Transplant outcomes
| . | Entire cohort n = 306 . | TCRαβ-HSCT n = 167 . | PTCY-HSCT n = 139 . | P value . | |||
|---|---|---|---|---|---|---|---|
| Missing data . | Results . | Missing data . | Results . | Missing data . | Results . | ||
| Neutrophil recovery, n (%) | 12 (3.9) | 255 (86.7) | 9 (5.4) | 134 (84.8) | 3 (2.2) | 121 (89.0) | .381∗ |
| Median day to neutrophil recovery (range)¶ | 0 (0.0) | 15.0 (5.0-139.0) | 0 (0.0) | 13.5 (8.0-38.0) | 0 (0.0) | 17.0 (5.0-139.0) | <.001‡ |
| Platelet recovery, n (%) | 20 (6.5) | 230 (80.4) | 14 (8.4) | 123 (80.4) | 6 (4.3) | 107 (80.5) | >.999∗ |
| Median day to platelet recovery (range)¶ | 0 (0.0) | 16.0 (5.0-613.0) | 0 (0.0) | 12.0 (5.0-377.0) | 0 (0.0) | 21.0 (9.0-613.0) | <.001‡ |
| Graft failure, CIN (95% CI) | 46 (15.0) | 26 (15.6) | 20 (14.4) | ||||
| 1-year CIN of all graft failure | 13% (9%-17%) | 15% (9%-21%) | 11% (5%-17%) | .414§ | |||
| Day 60 CIN of primary graft failure | 8% (4%-11%) | 10% (5%-15%) | 5% (1%-9%) | .048§ | |||
| 1-year CIN of secondary graft failure | 4% (2%-7%) | 3% (0%-6%) | 6% (2%-10%) | .144§ | |||
| Secondary procedures (DLI or CD34+ stem cell boost), n (%) | 26 (8.5) | 13 (4.6) | 23 (13.8) | 9 (6.2) | 3 (2.2) | 4 (2.9) | .303∗ |
| Second conditioned HSCT, n (%) | 0 (0.0) | 40 (13.1) | 0 (0.0) | 29 (17.4) | 0 (0.0) | 11 (7.9) | .023∗ |
| Veno-occlusive disease, n (%) | 5 (1.6) | 28 (9.3) | 5 (3.0) | 8 (4.9) | 0 (0.0) | 20 (14.4) | .009∗ |
| Hemorrhagic cystitis, n (%) | 24 (7.8) | 18 (6.4) | 23 (13.8) | 5 (3.5) | 1 (0.7) | 13 (9.4) | .072∗ |
| Acute kidney injury, n (%) | 51 (16.7) | 20 (7.8) | 14 (8.4) | 7 (4.6) | 37 (26.6) | 13 (12.7) | .032∗ |
| Transplant-associated microangiopathy, n (%) | 52 (17.0) | 12 (4.7) | 14 (8.4) | 5 (3.3) | 38 (27.3) | 7 (6.9) | .229† |
| Cardiac complications, n (%) | 33 (10.8) | 24 (8.8) | 30 (18.0) | 10 (7.3) | 3 (2.2) | 14 (10.3) | .509∗ |
| Heart failure | 2 (0.7) | 2 (1.5) | 0 (0.0) | ||||
| Pericardial effusion | 7 (2.6) | 4 (2.9) | 3 (2.2) | ||||
| Pericarditis | 1 (0.4) | 0 (0.0) | 1 (0.7) | ||||
| Cardiomyopathy | 1 (0.4) | 0 (0.0) | 1 (0.7) | ||||
| Arrhythmia | 3 (1.1) | 0 (0.0) | 3 (2.2) | ||||
| Other∗∗ | 10 (3.7) | 4 (2.9) | 6 (4.4) | ||||
| Pulmonary complications, n (%) | 33 (10.8) | 85 (31.1) | 30 (18.0) | 33 (24.1) | 3 (2.2) | 52 (38.2) | .017∗ |
| Infection | 34 (12.5) | 14 (10.2) | 20 (14.7) | ||||
| Noninfectious pulmonary complications | 51 (18.7) | 19 (13.9) | 32 (23.5) | ||||
| Pneumonitis | 25 (9.2) | 9 (6.6) | 16 (11.8) | ||||
| Idiopathic lung disease/pneumonia | 6 (2.2) | 2 (1.5) | 4 (2.9) | ||||
| Diffuse alveolar hemorrhage | 2 (0.7) | 0 (0.0) | 2 (1.5) | ||||
| Pulmonary hypertension | 4 (1.5) | 2 (1.5) | 2 (1.5) | ||||
| Other†† | 14 (5.1) | 6 (4.4) | 8 (5.9) | ||||
| Encephalopathy, n (%) | 52 (17.0) | 15 (5.9) | 15 (9.0) | 8 (5.3) | 37 (26.6) | 7 (6.9) | .796∗ |
| Autoimmune cytopenia, n (%) | 4 (1.3) | 45 (14.9) | 4 (2.4) | 29 (17.8) | 0 (0.0) | 16 (11.5) | .172∗ |
| AIHA | 16 (5.3) | 10 (6.1) | 6 (4.3) | ||||
| ITP | 16 (5.3) | 9 (5.5) | 7 (5.0) | ||||
| AIN | 3 (1.0) | 2 (1.2) | 1 (0.7) | ||||
| AIHA + ITP | 3 (1.0) | 2 (1.2) | 1 (0.7) | ||||
| ITP + AIN | 1 (0.3) | 1 (0.6) | 0 (0.0) | ||||
| AIHA + ITP + AIN | 6 (2.0) | 5 (3.1) | 1 (0.7) | ||||
| CMV infection, n (%) | 34 (11.1) | 109 (40.1) | 18 (10.8) | 60 (40.3) | 16 (11.5) | 49 (39.8) | >.999∗ |
| Persistent from pre-transplant | 26 (9.6) | 18 (12.1) | 8 (6.5) | ||||
| Posttransplant CMV | 83 (30.5) | 42 (28.2) | 41 (33.3) | ||||
| CMV disease | 14 (5.1) | 6 (4.0) | 8 (6.5) | ||||
| CMV infection | 69 (25.4) | 36 (24.2) | 33 (26.8) | ||||
| Adenoviremia, n (%) | 4 (1.3) | 41 (13.6) | 3 (1.8) | 30 (18.3) | 1 (0.7) | 11 (8.0) | .015∗ |
| Persistent from pre-transplant | 6 (2.0) | 4 (2.4) | 2 (1.4) | ||||
| Posttransplant adenoviremia | 35 (11.6) | 26 (15.9) | 9 (6.5) | ||||
| Asymptomatic | 23 (7.6) | 18 (11.0) | 5 (3.6) | ||||
| Symptomatic | 12 (4.0) | 8 (4.9) | 4 (2.9) | ||||
| EBV viremia, n (%) | 1 (0.3) | 29 (9.5) | 0 (0.0) | 16 (9.6) | 1 (0.7) | 13 (9.4) | >.999∗ |
| Persistent from pre-transplant | 6 (2.0) | 2 (1.2) | 4 (2.9) | ||||
| Posttransplant EBV viremia | 23 (7.5) | 14 (8.4) | 9 (6.5) | ||||
| Asymptomatic | 17 (5.6) | 10 (6.0) | 7 (5.1) | ||||
| Symptomatic | 6 (2.0) | 4 (2.4) | 2 (1.4) | ||||
| Posttransplant lymphoproliferative disease, n (%) | 56 (18.3) | 5 (2.0) | 2 (1.2) | 3 (1.8) | 54 (38.8) | 2 (2.4) | >.999† |
| Cause of death,‡‡ n (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | .173† | |||
| Transplant related | 56 (69.1) | 23 (65.7) | 33 (71.7) | ||||
| Disease related | 17 (21.0) | 6 (17.1) | 11 (23.9) | ||||
| Other | 8 (9.9) | 6 (17.1) | 2 (4.3) | ||||
| . | Entire cohort n = 306 . | TCRαβ-HSCT n = 167 . | PTCY-HSCT n = 139 . | P value . | |||
|---|---|---|---|---|---|---|---|
| Missing data . | Results . | Missing data . | Results . | Missing data . | Results . | ||
| Neutrophil recovery, n (%) | 12 (3.9) | 255 (86.7) | 9 (5.4) | 134 (84.8) | 3 (2.2) | 121 (89.0) | .381∗ |
| Median day to neutrophil recovery (range)¶ | 0 (0.0) | 15.0 (5.0-139.0) | 0 (0.0) | 13.5 (8.0-38.0) | 0 (0.0) | 17.0 (5.0-139.0) | <.001‡ |
| Platelet recovery, n (%) | 20 (6.5) | 230 (80.4) | 14 (8.4) | 123 (80.4) | 6 (4.3) | 107 (80.5) | >.999∗ |
| Median day to platelet recovery (range)¶ | 0 (0.0) | 16.0 (5.0-613.0) | 0 (0.0) | 12.0 (5.0-377.0) | 0 (0.0) | 21.0 (9.0-613.0) | <.001‡ |
| Graft failure, CIN (95% CI) | 46 (15.0) | 26 (15.6) | 20 (14.4) | ||||
| 1-year CIN of all graft failure | 13% (9%-17%) | 15% (9%-21%) | 11% (5%-17%) | .414§ | |||
| Day 60 CIN of primary graft failure | 8% (4%-11%) | 10% (5%-15%) | 5% (1%-9%) | .048§ | |||
| 1-year CIN of secondary graft failure | 4% (2%-7%) | 3% (0%-6%) | 6% (2%-10%) | .144§ | |||
| Secondary procedures (DLI or CD34+ stem cell boost), n (%) | 26 (8.5) | 13 (4.6) | 23 (13.8) | 9 (6.2) | 3 (2.2) | 4 (2.9) | .303∗ |
| Second conditioned HSCT, n (%) | 0 (0.0) | 40 (13.1) | 0 (0.0) | 29 (17.4) | 0 (0.0) | 11 (7.9) | .023∗ |
| Veno-occlusive disease, n (%) | 5 (1.6) | 28 (9.3) | 5 (3.0) | 8 (4.9) | 0 (0.0) | 20 (14.4) | .009∗ |
| Hemorrhagic cystitis, n (%) | 24 (7.8) | 18 (6.4) | 23 (13.8) | 5 (3.5) | 1 (0.7) | 13 (9.4) | .072∗ |
| Acute kidney injury, n (%) | 51 (16.7) | 20 (7.8) | 14 (8.4) | 7 (4.6) | 37 (26.6) | 13 (12.7) | .032∗ |
| Transplant-associated microangiopathy, n (%) | 52 (17.0) | 12 (4.7) | 14 (8.4) | 5 (3.3) | 38 (27.3) | 7 (6.9) | .229† |
| Cardiac complications, n (%) | 33 (10.8) | 24 (8.8) | 30 (18.0) | 10 (7.3) | 3 (2.2) | 14 (10.3) | .509∗ |
| Heart failure | 2 (0.7) | 2 (1.5) | 0 (0.0) | ||||
| Pericardial effusion | 7 (2.6) | 4 (2.9) | 3 (2.2) | ||||
| Pericarditis | 1 (0.4) | 0 (0.0) | 1 (0.7) | ||||
| Cardiomyopathy | 1 (0.4) | 0 (0.0) | 1 (0.7) | ||||
| Arrhythmia | 3 (1.1) | 0 (0.0) | 3 (2.2) | ||||
| Other∗∗ | 10 (3.7) | 4 (2.9) | 6 (4.4) | ||||
| Pulmonary complications, n (%) | 33 (10.8) | 85 (31.1) | 30 (18.0) | 33 (24.1) | 3 (2.2) | 52 (38.2) | .017∗ |
| Infection | 34 (12.5) | 14 (10.2) | 20 (14.7) | ||||
| Noninfectious pulmonary complications | 51 (18.7) | 19 (13.9) | 32 (23.5) | ||||
| Pneumonitis | 25 (9.2) | 9 (6.6) | 16 (11.8) | ||||
| Idiopathic lung disease/pneumonia | 6 (2.2) | 2 (1.5) | 4 (2.9) | ||||
| Diffuse alveolar hemorrhage | 2 (0.7) | 0 (0.0) | 2 (1.5) | ||||
| Pulmonary hypertension | 4 (1.5) | 2 (1.5) | 2 (1.5) | ||||
| Other†† | 14 (5.1) | 6 (4.4) | 8 (5.9) | ||||
| Encephalopathy, n (%) | 52 (17.0) | 15 (5.9) | 15 (9.0) | 8 (5.3) | 37 (26.6) | 7 (6.9) | .796∗ |
| Autoimmune cytopenia, n (%) | 4 (1.3) | 45 (14.9) | 4 (2.4) | 29 (17.8) | 0 (0.0) | 16 (11.5) | .172∗ |
| AIHA | 16 (5.3) | 10 (6.1) | 6 (4.3) | ||||
| ITP | 16 (5.3) | 9 (5.5) | 7 (5.0) | ||||
| AIN | 3 (1.0) | 2 (1.2) | 1 (0.7) | ||||
| AIHA + ITP | 3 (1.0) | 2 (1.2) | 1 (0.7) | ||||
| ITP + AIN | 1 (0.3) | 1 (0.6) | 0 (0.0) | ||||
| AIHA + ITP + AIN | 6 (2.0) | 5 (3.1) | 1 (0.7) | ||||
| CMV infection, n (%) | 34 (11.1) | 109 (40.1) | 18 (10.8) | 60 (40.3) | 16 (11.5) | 49 (39.8) | >.999∗ |
| Persistent from pre-transplant | 26 (9.6) | 18 (12.1) | 8 (6.5) | ||||
| Posttransplant CMV | 83 (30.5) | 42 (28.2) | 41 (33.3) | ||||
| CMV disease | 14 (5.1) | 6 (4.0) | 8 (6.5) | ||||
| CMV infection | 69 (25.4) | 36 (24.2) | 33 (26.8) | ||||
| Adenoviremia, n (%) | 4 (1.3) | 41 (13.6) | 3 (1.8) | 30 (18.3) | 1 (0.7) | 11 (8.0) | .015∗ |
| Persistent from pre-transplant | 6 (2.0) | 4 (2.4) | 2 (1.4) | ||||
| Posttransplant adenoviremia | 35 (11.6) | 26 (15.9) | 9 (6.5) | ||||
| Asymptomatic | 23 (7.6) | 18 (11.0) | 5 (3.6) | ||||
| Symptomatic | 12 (4.0) | 8 (4.9) | 4 (2.9) | ||||
| EBV viremia, n (%) | 1 (0.3) | 29 (9.5) | 0 (0.0) | 16 (9.6) | 1 (0.7) | 13 (9.4) | >.999∗ |
| Persistent from pre-transplant | 6 (2.0) | 2 (1.2) | 4 (2.9) | ||||
| Posttransplant EBV viremia | 23 (7.5) | 14 (8.4) | 9 (6.5) | ||||
| Asymptomatic | 17 (5.6) | 10 (6.0) | 7 (5.1) | ||||
| Symptomatic | 6 (2.0) | 4 (2.4) | 2 (1.4) | ||||
| Posttransplant lymphoproliferative disease, n (%) | 56 (18.3) | 5 (2.0) | 2 (1.2) | 3 (1.8) | 54 (38.8) | 2 (2.4) | >.999† |
| Cause of death,‡‡ n (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | .173† | |||
| Transplant related | 56 (69.1) | 23 (65.7) | 33 (71.7) | ||||
| Disease related | 17 (21.0) | 6 (17.1) | 11 (23.9) | ||||
| Other | 8 (9.9) | 6 (17.1) | 2 (4.3) | ||||
Boldface indicates significant P values.
AIHA, autoimmune hemolytic anemia; AIN, autoimmune neutropenia; ATG, antithymocyte globulin; ITP, immune thrombocytopenia; MMFD, mismatched donor; MMUD, mismatched unrelated donor.
Calculated via the χ2 test.
Calculated via Fisher exact test.
Calculated via the Wilcoxon rank sum test.
Calculated via Gray test. This tests for differences in the cumulative incidence curves for the given event between the 2 treatments. groups across the entire follow-up period. (That is, if there is any difference between the cumulative incidence curves.) Therefore, it tests for more than only the difference in the cumulative incidence estimates at the indicated time point.
Reported among patients who achieved neutrophil/platelet recovery.
The other cardiac complications include: atrial thrombus, cardiac arrest, cardiogenic shock, and hypertension.
The other pulmonary complications include: lung fibrosis, alveolitis, pulmonary embolism, viral pneumonia, acute respiratory distress syndrome, right pleural effusion, relapsed pneumatocele, and respiratory failure.
Reported among patients who died.